- Home
- VRDN vs DVAX Comparison
VRDN vs DVAX Comparison
Compare VRDN & DVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRDN
- DVAX
- Stock Information
- Founded
- VRDN 2006
- DVAX 1996
- Country
- VRDN United States
- DVAX United States
- Employees
- VRDN N/A
- DVAX N/A
- Industry
- VRDN Medical Specialities
- DVAX Biotechnology: Pharmaceutical Preparations
- Sector
- VRDN Health Care
- DVAX Health Care
- Exchange
- VRDN Nasdaq
- DVAX Nasdaq
- Market Cap
- VRDN 1.6B
- DVAX 1.7B
- IPO Year
- VRDN N/A
- DVAX 2004
- Fundamental
- Price
- VRDN $19.64
- DVAX $12.92
- Analyst Decision
- VRDN Strong Buy
- DVAX Buy
- Analyst Count
- VRDN 11
- DVAX 2
- Target Price
- VRDN $37.63
- DVAX $22.00
- AVG Volume (30 Days)
- VRDN 1.4M
- DVAX 1.3M
- Earning Date
- VRDN 11-12-2024
- DVAX 11-07-2024
- Dividend Yield
- VRDN N/A
- DVAX N/A
- EPS Growth
- VRDN N/A
- DVAX N/A
- EPS
- VRDN N/A
- DVAX 0.15
- Revenue
- VRDN $302,000.00
- DVAX $260,810,000.00
- Revenue This Year
- VRDN $2.55
- DVAX $21.64
- Revenue Next Year
- VRDN N/A
- DVAX $19.81
- P/E Ratio
- VRDN N/A
- DVAX $85.33
- Revenue Growth
- VRDN N/A
- DVAX N/A
- 52 Week Low
- VRDN $11.40
- DVAX $9.74
- 52 Week High
- VRDN $27.20
- DVAX $15.01
- Technical
- Relative Strength Index (RSI)
- VRDN 49.14
- DVAX 58.43
- Support Level
- VRDN $20.06
- DVAX $12.71
- Resistance Level
- VRDN $23.65
- DVAX $13.17
- Average True Range (ATR)
- VRDN 1.05
- DVAX 0.28
- MACD
- VRDN 0.16
- DVAX -0.04
- Stochastic Oscillator
- VRDN 49.45
- DVAX 57.69
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease.
About DVAX Dynavax Technologies Corporation
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.